Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.36 |
| ▸ | CTSA | P10619 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CBLB | Q13191 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.34 |
| ▸ | PRKCB | P05771 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22857024 | 0.86 | RET (0.42) | RETSMYD3CTSAMGLLACKR3 | |
| SCHEMBL20147628 | 0.86 | RET (0.40) | RETSMYD3CTSAMGLLCBLB | |
| SCHEMBL20068970 | 0.81 | P2RX7 (0.50) | RETCTSAPRKCBCNR2 | |
| SCHEMBL20068965 | 0.80 | RET (0.44) | RETSMYD3CTSA | |
| SCHEMBL20069632 | 0.77 | GABRA1 (0.41) | RETSMYD3ADORA2ACNR2 | |
| SCHEMBL20068969 | 0.76 | RET (0.43) | RETMAPT | |
| SCHEMBL20069105 | 0.76 | IRAK4 (0.43) | RETSMYD3MGLL | |
| SCHEMBL20070356 | 0.75 | RET (0.42) | RETADORA2ACNR2ADAM17 | |
| SCHEMBL20070353 | 0.73 | RET (0.42) | RETCTSALMNAMAPTMCHR1 | |
| SCHEMBL20068981 | 0.73 | RET (0.42) | RETSMYD3PRKCBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885SMYD3 1177/4885CTSA 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.